MedTrace Logo

A Study of ZT002 Injection in Participants With Overweight or Obesity

NCT06371326 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-01-16

No results posted yet for this study

Summary

This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.

Conditions

  • Overweight or Obesity

Interventions

DRUG

ZT002 Injection

Participants will receive ZT002 by subcutaneous (SC) injection.

DRUG

Placebo

Participants will receive Placebo by subcutaneous (SC) injection.

Sponsors & Collaborators

  • Beijing QL Biopharmaceutical Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaoli Li, Master · First Affiliated Hospital of Bengbu Medical College

  • Huan Zhou, PhD · First Affiliated Hospital of Bengbu Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-21
Primary Completion
2024-04-15
Completion
2024-10-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06371326 on ClinicalTrials.gov